The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed ...

The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not ...

5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer ...

Please provide your email address to receive an email when new articles are posted on . “Sintilimab [Tyvyt; Eli Lilly & Co., Innovent Biologics] is a fully human IgG4 monoclonal antibody that blocks ...

Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: More Questions Than Answers Ramalingam et al 1 reported the results of a phase III trial, ECOG-ACRIN 5508, which compared ...

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer. Tagrisso(osimertinib) ...

The UK's cost containment agency, the National Institute for Health and Clinical Excellence (NICE), released draft guidance on 22 February 2013 that does not recommend Lilly's pemetrexed ...

Introduction: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide. Treatment options are limited, and response to chemotherapy is poor. The ...

"The claim that pemetrexed is superior in adenocarcinoma is one that is not supported by the US FDA [US Food and Drug Administration] and is not supported by a careful consideration of the evidence," ...